TrustCore Financial Services’s Supernus Pharmaceuticals SUPN Stock Holding History

TrustCore Financial Services’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-28	Closed	-$1K	–	939
2019 Q1	$1K	Buy	+28	New	+$1.04K	﹤0.01%	818
2018 Q4	–	Sell	-28	Closed	-$1K	–	744
2018 Q3	$1K	Sell	28 -24	-46%	-$1.19K	﹤0.01%	814
2018 Q2	$3K	Buy	+52	New	+$2.69K	﹤0.01%	778

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

TrustCore Financial Services's SUPN Position: Q2 2019 in Review

TrustCore Financial Services sold out of Supernus Pharmaceuticals (SUPN) in Q2 2019, closing a stake of 28 shares — an estimated $1K sold.

TrustCore Financial Services first reported a position in SUPN in Q2 2018 and held it in 3 quarters. The position peaked at $3K in Q2 2018. 272 funds tracked by Wall St. Rank hold SUPN as of Q2 2019.

TrustCore Financial Services reported no remaining Supernus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
TrustCore Financial Services sold 28 Supernus Pharmaceuticals shares in Q2 2019, an estimated $1K.
TrustCore Financial Services first reported a position in Supernus Pharmaceuticals in Q2 2018 and held it in 3 quarters.
TrustCore Financial Services's Supernus Pharmaceuticals position peaked at $3K in Q2 2018.
272 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2019.

Based on TrustCore Financial Services's 13F filing for Q2 2019, filed 25 Jul 2019.